Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.42
-0.20 (-1.07%)
At close: Nov 21, 2024, 4:00 PM
18.35
-0.07 (-0.38%)
After-hours: Nov 21, 2024, 4:03 PM EST
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
105
Market Cap
13.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | 860.00K | 49.46K | 6.10% |
| Dec 31, 2019 | 810.55K | -56.28M | -98.58% |
| Jan 31, 2019 | Pro | Pro | Pro |
| Jan 31, 2018 | Pro | Pro | Pro |
| Jan 31, 2017 | Pro | Pro | Pro |
| Jan 31, 2016 | Pro | Pro | Pro |
| Jan 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tenet Healthcare | 20.97B |
| Viatris | 15.05B |
| ICON Public Limited Company | 8.31B |
| Avantor | 6.82B |
| Moderna | 5.08B |
| Incyte | 4.08B |
| Align Technology | 3.96B |
| United Therapeutics | 2.76B |
SMMT News
- 17 days ago - Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Benzinga
- 22 days ago - Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 - Business Wire
- 4 weeks ago - Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024 - Business Wire
- 6 weeks ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track - Investopedia
- 7 weeks ago - Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC - Business Wire
- 2 months ago - Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial - Seeking Alpha